About: A rapid and quantitative assay for measuring neutralizing antibodies of Coxsackievirus B3

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: A rapid and quantitative assay for measuring neutralizing antibodies of Coxsackievirus B3 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	A rapid and quantitative assay for measuring neutralizing antibodies of Coxsackievirus B3
Creator	Li, Wenhui Zhu, Fengcai Liang, Zhenglun Wu, Xing Chen, Pan Xu, Miao Hao, Xiaotian Mao, Qunying Bian, Lianlian Gao, Fan
Source	Elsevier; Medline; PMC
abstract	Abstract Coxsackievirus B3 (CVB3) infection has been found to account for an increasing proportion cases of hand, foot and mouth disease (HFMD) in recent epidemiology studies. CVB3 is a single stranded, non-enveloped RNA virus and the infection can cause prominent health threat to pre-school children. Here, by taking approaches of reverse genetics, we established a single-round infection system for CVB3. The pseudovirus was produced by sequential transfection of CVB3 capsid expresser plasmid and CVB3 replicon RNA bearing firefly luciferase as a reporter. The CVB3 pseudovirus system was used for quantifying neutralizing antibody (NtAb) levels of 720 human serum samples and showed superior specificity and sensitivity comparing traditional cytopathic effect (CPE) assay. Furthermore, we compared the seroprevalence of CVB3 NtAbs in pre-school children and healthy adults, and found that only 11.94% of pre-school children were NtAbs positive which suggested that most children were naive to CVB3 infection; while there is much higher positive rate in adults (60%) indicating that most adults have experienced CVB3 infection during childhood. This rapid and quantitative assay greatly facilitates evaluating the level of NtAbs against CVB3 in populations and will help to advance CVB3 vaccine development.
has issue date	2016-06-30(xsd:dateTime)
bibo:doi	10.1016/j.jviromet.2016.02.010
bibo:pmid	26947399
has license	els-covid
sha1sum (hex)	f9e71114eecf03cedc124d3f670b22fdf3a476b4
schema:url	https://doi.org/10.1016/j.jviromet.2016.02.010
resource representing a document's title	A rapid and quantitative assay for measuring neutralizing antibodies of Coxsackievirus B3
has PubMed Central identifier	PMC7113863
has PubMed identifier	26947399
schema:publication	Journal of Virological Methods
resource representing a document's body	covid:f9e71114eecf03cedc124d3f670b22fdf3a476b4#body_text
is schema:about of	named entity 'indicating' named entity 'quantifying' named entity 'produced' named entity 'adults' named entity 'studies' named entity 'SENSITIVITY' named entity 'LEVEL' named entity 'ADULTS' named entity 'CAUSE' named entity 'HERE' named entity 'COXSACKIEVIRUS B3' named entity 'HIGHER' named entity 'SCHOOL CHILDREN' named entity 'STUDIES' named entity 'MUCH' named entity 'INDICATING' named entity 'FIREFLY LUCIFERASE' named entity 'POSITIVE RATE' named entity 'EVALUATING' named entity 'EXPERIENCED' named entity 'USED' named entity 'FOUND' named entity 'REPORTER' named entity 'SEROPREVALENCE' named entity 'HUMAN SERUM' named entity 'REVERSE GENETICS' named entity 'APPROACHES' named entity 'RNA VIRUS' named entity 'NEUTRALIZING ANTIBODY' named entity '720' named entity 'RECENT' named entity 'POPULATIONS' named entity 'COXSACKIEVIRUS B3' named entity 'ASSAY' named entity 'IS A' named entity 'POSITIVE' named entity '2860' named entity 'PSEUDOVIRUS' named entity 'ADVANCE' named entity 'CYTOPATHIC EFFECT' named entity 'TRANSFECTION' named entity 'CHILDHOOD' named entity 'SEQUENTIAL' named entity 'THREAT' named entity 'CAPSID' named entity 'HAVE' named entity 'SAMPLES' named entity 'SINGLE' named entity 'COMPARED' named entity 'TAKING' named entity 'EPIDEMIOLOGY' named entity 'ACCOUNT' named entity 'TRADITIONAL' named entity 'QUANTITATIVE' named entity 'ASSAY' named entity 'HAND' named entity 'CHILDREN' named entity 'NEUTRALIZING ANTIBODIES' named entity 'RAPID' named entity 'CASES' named entity 'HEALTHY' named entity 'FOOT AND MOUTH DISEASE' named entity 'VACCINE DEVELOPMENT' named entity 'LEVELS' named entity 'SPECIFICITY' named entity 'ROUND' named entity 'COMPARING' named entity 'PLASMID' named entity 'QUANTITATIVE' named entity 'REPLICON' named entity 'HELP' named entity 'NON-'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software